bioAffinity Technologies, Inc.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
- Ticker
- BIAF
- Trading on
- NASDAQ
- ISIN
- -
- Industry
- Diagnostics & Research
- Sector
- Healthcare
- CEO
- Maria Zannes J.D.
- Headquarters
- 3300 Nacogdoches Road, San Antonio, TX, United States, 78217
- Employees
- 57
- Website
- https://bioaffinitytech.com
Metrics
Earnings per share (EPS) forecast
| Q4 • 25 | Q1 • 26 | Q2 • 26 | |
|---|---|---|---|
| Actual | -$10.46 | -$0.81 | -$0.64 |
| Expected | - | - | - |
| Surprise | - | - | - |
| Beat | Beat | Current |
Financial Performance
| Q2 • 26 | Q3 • 26 | QoQ growth | |
|---|---|---|---|
| Revenue | $1.5M | $1.1M | -29.15% |
| Net income | $-3.4M | $-5.3M | 56.77% |
| Profit margin | -222.83% | -493.05% | 121.26% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.
FAQs
01How much is a bioAffinity Technologies, Inc. share?
bioAffinity Technologies, Inc. shares are currently traded for undefined per share.
02How many shares does bioAffinity Technologies, Inc. have?
bioAffinity Technologies, Inc. currently has 1.8M shares.
03Does bioAffinity Technologies, Inc. pay dividends?
No, bioAffinity Technologies, Inc. doesn't pay dividends.
04What is bioAffinity Technologies, Inc. 52 week high?
bioAffinity Technologies, Inc. 52 week high is $80.70.
05What is bioAffinity Technologies, Inc. 52 week low?
bioAffinity Technologies, Inc. 52 week low is $1.63.
06What is the 200-day moving average of bioAffinity Technologies, Inc.?
bioAffinity Technologies, Inc. 200-day moving average is $18.11.
07Who is bioAffinity Technologies, Inc. CEO?
The CEO of bioAffinity Technologies, Inc. is Maria Zannes J.D..
08How many employees bioAffinity Technologies, Inc. has?
bioAffinity Technologies, Inc. has 57 employees.
09What is the market cap of bioAffinity Technologies, Inc.?
The market cap of bioAffinity Technologies, Inc. is $3.3M.
10What is the P/E of bioAffinity Technologies, Inc.?
The current P/E of bioAffinity Technologies, Inc. is null.
11What is the EPS of bioAffinity Technologies, Inc.?
The EPS of bioAffinity Technologies, Inc. is -$40.37.
12What is the PEG Ratio of bioAffinity Technologies, Inc.?
The PEG Ratio of bioAffinity Technologies, Inc. is null.


